- Home
- DOUG vs ABOS Comparison
DOUG vs ABOS Comparison
Compare DOUG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | ABOS |
|---|---|---|
| Founded | 1911 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 113.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOUG | ABOS |
|---|---|---|
| Price | $2.82 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 292.1K | 151.0K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,030,928,000.00 | N/A |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.67 | N/A |
| 52 Week Low | $1.48 | $0.86 |
| 52 Week High | $3.20 | $2.46 |
Technical Indicators
Market Signals| Indicator | DOUG | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 62.49 | 60.73 |
| Support Level | $2.66 | $1.87 |
| Resistance Level | $2.70 | $2.02 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 87.27 | 91.38 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.